About the Study
This study is assessing whether a new targeted therapy (olomorasib) in combination with standard of care anti-cancer drugs (including immunotherapy and chemotherapy) is more effective than just standard of care in participants with untreated advanced non-small cell lung cancer with a KRAS G12C mutation.
Who Can Participate
Participants must:
- Be 18 years and older
- Have non-small cell lung cancer that is advanced or has spread to another part(s) of the body
- Have cancer with a change in the KRAS G12C gene
- Have a known programmed death-ligand 1 (PD-L1) expression of 0-100%. PD-L1 expression may predict how well the body responds to some types of treatment
- Be able to swallow capsules and/or tablets
- Be well enough to walk and do light work
What to Expect During Study Participation
Participation in the study is expected to last for up to approximately 3 years (including follow up).
Study Medication
This is double-blind randomised controlled trial with two different study groups. Each participant will be randomly assigned to one group – either receiving olomorasib OR the placebo, both with standard of care medication.
